VG081821 / Vimgreen Pharma - LARVOL DELTA

Vimgreen Completes Enrollment of Its Phase 2 Clinical Trial Evaluating VG081821AC for the Treatment of Parkinson’s Disease (PRNewswire) - "Vimgreen Pharmaceuticals...announced today the completion of enrollment of its Phase 2 clinical trial of VG081821AC...for the treatment of early-to-mid stage Parkinson's disease. A total of 150 participants have been enrolled and randomized into one of three cohorts, a high-dose VG081821 group, a low-dose VG081821 group, and a placebo group at a ratio of 1:1:1...The Phase 2 trial is to be completed in November."

Enrollment closed • Trial completion date • CNS Disorders • Parkinson's Disease